Inventor · disambiguated record
Roel Funke
Also filed as: FUNKE ROEL · FUNKE ROEL P
5 granted patents·28 pending applications·3 citations·filing 2002–2021
69Inventor score
Top patents by PatentIndex Score
33 records- 0179US7993829B2HPRP4s modifiers of the p53 pathway and methods of useEXELIXIS INC·Filed 2007·Granted Aug 9, 2011·2 cites·10 claims
- 0268US2008166709A1MARKs as Modifiers of the p53 Pathway and Methods of UseEXELIXIS INC·Filed 2007·Application pending·0 cites
- 0366US2008241131A1SPHKS as modifiers of the p53 pathway and methods of useEXELIXIS INC·Filed 2008·Application pending·0 cites
- 0459US2010275275A1HADHs as Modifiers of the p21 Pathway and Methods of UseEXELIXIS INC·Filed 2009·Application pending·0 cites
- 0554US2006160764A1LIMKs as modifiers of p53 pathway and methods of useEXELIXIS INC·Filed 2006·Application pending·0 cites
- 0653US7049088B2PRMTs as modifiers of the p53 pathway and methods of useEXELIXIS INC·Filed 2002·Granted May 23, 2006·1 cites·2 claims
- 0752US8153384B2Marks as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2010·Granted Apr 10, 2012·0 cites·15 claims
- 0851US8268548B2MAP3Ks as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2007·Granted Sep 18, 2012·0 cites·12 claims
- 0951US2005181481A1HADHs as modifiers of the p21 pathway and methods of useEXELIXIS INC·Filed 2005·Application pending·0 cites
- 1051US2005227228A1Map3ks as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2002·Application pending·0 cites
- 1151US2005186200A1HADHs as modifiers of the p21 pathway and methods of useEXELIXIS INC·Filed 2005·Application pending·0 cites
- 1250US2003087266A1IGs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 1350US2011159508A1GFATS as Modifiers of the P53 Pathway and Methods of UseEXELIXIS INC·Filed 2010·Application pending·0 cites
- 1448US2003027230A1HPRP4s as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 1547US6927022B2HADHs as modifiers of the p21 pathway and methods of useEXELIXIS INC·Filed 2002·Granted Aug 9, 2005·0 cites·21 claims
- 1647US2005112568A1Dgks as modifiers of the p53 pathwha and methods of useFiled 2002·Application pending·0 cites
- 1747US2003013144A1HS2STs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 1847US2005170344A1Chds as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 1947US2003165809A1MARKs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 2047US2002192695A1PIBs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 2147US2003027188A1SLC7s as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 2247US2003036076A1CADs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 2346US2006121457A1Gfats as modifiers of the p53 pathway and methods of useEXELIXIS INC·Filed 2002·Application pending·0 cites
- 2446US2021208145A1Diagnostic and therapeutic methods for triple-negative breast cancerGENENTECH INC·Filed 2021·Application pending·0 cites
- 2541US2003036078A1P5CRs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 2641US2007134732A1Lces as modifiers of the p53 pathway and methods of useEXELIXIS INC·Filed 2002·Application pending·0 cites
- 2741US2003138431A1LRRCAPs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 2840US2006252035A1Sphks as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2002·Application pending·0 cites
- 2939US2003022209A1ADSLs as modifiers of the p53 pathway and methods of useFiled 2002·Application pending·0 cites
- 3037US2006024673A1Slc2as as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2002·Application pending·0 cites
- 3136US2006024665A1PRMTs as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2005·Application pending·0 cites
- 3236US2013004498A1Dosing for treatment with anti-egfl7 antibodiesGENENTECH INC·Filed 2012·Application pending·0 cites
- 3334US2006121041A1Gpcs as modifiers of the irrtk p21 pathways and methods of useFRIEDMAN LORI·Filed 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Roel Funke files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →